prikaz prve stranice dokumenta Reactogenicity and Peak Anti-RBD-S1 IgG Concentrations in Individuals with No Prior COVID-19 Infection Vaccinated with Different SARS-CoV-2 Vaccines
Pristup korisnicima matične ustanove
Znanstveni rad - Izvorni znanstveni rad
Reactogenicity and Peak Anti-RBD-S1 IgG Concentrations in Individuals with No Prior COVID-19 Infection Vaccinated with Different SARS-CoV-2 Vaccines
Laboratory Medicine, 55 (2023), 2; 162-168. https://doi.org/10.1093/labmed/lmad044
Milevoj Kopcinovic, Lara; Unić, Adriana; Nikolac Gabaj, Nora; Miler, Marijana; Vrtaric, Alen; Bozovic, Marija; Stefanovic, Mario

Citirajte ovaj rad

Milevoj Kopcinovic, L., Unić, A., Nikolac Gabaj, N., Miler, M., Vrtaric, A., Bozovic, M. i Stefanovic, M. (2023). Reactogenicity and Peak Anti-RBD-S1 IgG Concentrations in Individuals with No Prior COVID-19 Infection Vaccinated with Different SARS-CoV-2 Vaccines. Laboratory Medicine, 55. (2), 162-168. doi: 10.1093/labmed/lmad044

Milevoj Kopcinovic, Lara, et al. "Reactogenicity and Peak Anti-RBD-S1 IgG Concentrations in Individuals with No Prior COVID-19 Infection Vaccinated with Different SARS-CoV-2 Vaccines." Laboratory Medicine, vol. 55, br. 2, 2023, str. 162-168. https://doi.org/10.1093/labmed/lmad044

Milevoj Kopcinovic, Lara, Adriana Unić, Nora Nikolac Gabaj, Marijana Miler, Alen Vrtaric, Marija Bozovic i Mario Stefanovic. "Reactogenicity and Peak Anti-RBD-S1 IgG Concentrations in Individuals with No Prior COVID-19 Infection Vaccinated with Different SARS-CoV-2 Vaccines." Laboratory Medicine 55, br. 2 (2023): 162-168. https://doi.org/10.1093/labmed/lmad044

Milevoj Kopcinovic, L., et al. (2023) 'Reactogenicity and Peak Anti-RBD-S1 IgG Concentrations in Individuals with No Prior COVID-19 Infection Vaccinated with Different SARS-CoV-2 Vaccines', Laboratory Medicine, 55(2), str. 162-168. doi: 10.1093/labmed/lmad044

Milevoj Kopcinovic L, Unić A, Nikolac Gabaj N, Miler M, Vrtaric A, Bozovic M, i sur.. Reactogenicity and Peak Anti-RBD-S1 IgG Concentrations in Individuals with No Prior COVID-19 Infection Vaccinated with Different SARS-CoV-2 Vaccines. Laboratory Medicine [Internet]. 2023. [pristupljeno 17.11.2024.];55(2):162-168. doi: 10.1093/labmed/lmad044

L. Milevoj Kopcinovic, et al., "Reactogenicity and Peak Anti-RBD-S1 IgG Concentrations in Individuals with No Prior COVID-19 Infection Vaccinated with Different SARS-CoV-2 Vaccines", Laboratory Medicine, vol. 55, br. 2, str. 162-168, 2023. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:220:075141. [Citirano: 17.11.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:220:075141
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Reactogenicity and Peak Anti-RBD-S1 IgG Concentrations in Individuals with No Prior COVID-19 Infection Vaccinated with Different SARS-CoV-2 Vaccines
AutorLara Milevoj Kopcinovic
AutorAdriana Unić
AutorNora Nikolac Gabaj
AutorMarijana Miler
AutorAlen Vrtaric
AutorMarija Bozovic
AutorMario Stefanovic
Autorova ustanova(Klinički bolnički centar Sestre milosrdnice)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Klinička biokemija
Sažetak (engleski)
Objective: To investigate the association of immune response with vaccination adverse effects at peak anti–receptor-binding domain spike subunit 1 (anti-RBDS1) IgG after full vaccination with Comirnaty, Spikevax, or Vaxzevria. Methods: Anti-RBDS1 IgG concentrations after vaccination were determined in healthy adults vaccinated with the Comirnaty, Spikevax, and Vaxzevria vaccines. The association of reactogenicity and peak antibody response after vaccination was tested. Results: Anti-RBDS1 IgG values were significantly higher in the Comirnaty and Spikevax group, compared with the Vaxzevria group (P < .001). Fever and muscle pain were found to be significant independent predictors of peak anti-RBDS1 IgG in the Comirnaty and Spikevax groups (P = .03 and P = .02, respectively). The multivariate model, adjusted for covariates, showed that no association between reactogenicity and peak antibody concentrations was found in the Comirnaty, Spikevax, and Vaxzevria groups. Conclusions: No association between reactogenicity and peak anti-RBDS1 IgG after vaccination with the Comirnaty, Spikevax, and Vaxzevria vaccine was found.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran - međunarodna recenzija
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaLaboratory Medicine
Brojčani podacivol. 55, br. 2, str. 162-168
p-ISSN0007-5027
e-ISSN1943-7730
DOIhttps://doi.org/10.1093/labmed/lmad044
URN:NBNurn:nbn:hr:220:075141
Datum objave publikacije2023
URL dokumentahttps://academic.oup.com/labmed/article/55/2/162/7193314
Vrsta resursaTekst
Prava pristupaInstitucijski pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2024-07-15 13:54:09